Oramed enters royalty purchase on Gloperba/Elyxyb and rest-of-world license for Gloperba

ORAMED PHARMACEUTICALS INC.

Oramed gains right to 50% of 4% net sales royalty on Gloperba and Elyxyb worldwide (effectively 2% of net sales).
Oramed via RoyaltyVest Ltd gets exclusive rest-of-world license for Gloperba; net revenue split 50/50 with Scilex.
Agreements executed Feb 28, 2025 as part of deferral on $50M Scilex convertible notes due Oct 2026.
Oramed transferred 50% of RoyaltyVest shares to other investors; retains right to designate half the board.
Subordination Agreement grants first-priority lien on royalty collateral to Oramed and other purchasers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.